Significance of RAS mutations in pulmonary metastases of patients with colorectal cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Significance of RAS mutations in pulmonary metastases of patients with colorectal cancer

Published:2019-11-26 Issue:4 Volume:25 Page:641-650
ISSN:1341-9625
Container-title:International Journal of Clinical Oncology
language:en
Short-container-title:Int J Clin Oncol

Author:

Igarashi Takamichi,Shimizu Kimihiro,Usui Kengo,Yokobori Takehiko,Ohtaki Yoichi,Nakazawa Seshiru,Obayashi Kai,Yajima Toshiki,Nobusawa Sumihito,Ohkawa Takahiro,Katoh Ryuji,Motegi Yoko,Ogawa Hiroomi,Harimoto Norifumi,Ichihara Tatsuo,Mitani Yasumasa,Yokoo Hideaki,Mogi Akira,Shirabe Ken

Funder

Grants-in-Aid for Scientific Research from the Japan Society for the Promotion of Science

Ministry of Economy, Trade and Industry

The Japanese Ministry of Education, Culture, Sports, Science and Technology to the RIKEN Center for Life Science Technologies

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Hematology,General Medicine,Surgery

Link

http://link.springer.com/content/pdf/10.1007/s10147-019-01582-z.pdf

Reference28 articles.

1. Elbjeirami WM, Sughayer MA (2012) KRAS mutations and subtyping in colorectal cancer in Jordanian patients. Oncol Lett 4(4):705–710. https://doi.org/10.3892/ol.2012.785

2. De Roock W, Claes B, Bernasconi D et al (2010) Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 11(8):753–762. https://doi.org/10.1016/S1470-2045(10)70130-3

3. Heinemann V, von Weikersthal LF, Decker T et al (2014) FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol 15(10):1065–1075. https://doi.org/10.1016/S1470-2045(14)70330-4

4. Renaud S, Romain B, Falcoz PE et al (2015) KRAS and BRAF mutations are prognostic biomarkers in patients undergoing lung metastasectomy of colorectal cancer. Br J Cancer 112(4):720–728. https://doi.org/10.1038/bjc.2014.499

5. Yoshino T, Muro K, Yamaguchi K et al (2015) Clinical validation of a multiplex kit for RAS mutations in colorectal cancer: Results of the RASKET (RAS KEy Testing) prospective, multicenter study. EBioMed 2(4):317–323. https://doi.org/10.1016/j.ebiom.2015.02.007

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prognostic value and immune infiltration of novel signatures in colon cancer microenvironment;Cancer Cell International;2021-12

2. Histological growth patterns and molecular analysis of resected colorectal lung metastases;Pathology - Research and Practice;2021-06

3. Pulmonary metastasectomy in colorectal carcinoma;Journal of Thoracic Disease;2021-04

4. Lung metastases from colorectal cancer: a multidisciplinary approach and role of local treatment: a narrative review;AME Surgical Journal;2021-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3